Literature DB >> 3225692

Angiotensin converting enzyme inhibition decreases systolic blood pressure more than diastolic pressure as shown by ambulatory blood pressure monitoring.

R G Asmar1, B M Pannier, J P Santoni, M E Safar.   

Abstract

Non-invasive ambulatory blood pressure monitoring (Spacelabs 5200) was carried out before and 3 months after treatment with perindopril, a new angiotensin converting enzyme (ACE) inhibitor given at 4-8 mg once a day in the morning. Twenty-one patients with sustained essential uncomplicated hypertension were analysed. The 24-h mean values for systolic and diastolic blood pressure, their standard deviations (absolute variability) and their coefficients of variation were compared before and after the administration of perindopril, using a two-way analysis of variance. In order to determine whether perindopril could decrease systolic more than diastolic pressure, we evaluated the relationship between systolic and diastolic blood pressure as recorded by the Spacelabs monitor. The correlation coefficient between these two parameters was calculated before (r = 0.82) and after (r = 0.76) treatment. Comparison between the corresponding slopes indicated that, at any given value of diastolic blood pressure, systolic blood pressure was lower after than before the administration of perindopril.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3225692

Source DB:  PubMed          Journal:  J Hypertens Suppl        ISSN: 0952-1178


  7 in total

Review 1.  Perindopril. A review of its pharmacokinetics and clinical pharmacology.

Authors:  R J Macfadyen; K R Lees; J L Reid
Journal:  Drugs       Date:  1990       Impact factor: 9.546

Review 2.  First-line treatment in hypertension. Role of perindopril.

Authors:  A Zanchetti
Journal:  Drugs       Date:  1990       Impact factor: 9.546

3.  Clinical acceptability of ACE inhibitor therapy in mild to moderate hypertension, a comparison between perindopril and enalapril.

Authors:  L Alcocer; C Campos; J H Bahena; A Nacaud; J Parra Carillo; C Calvo; C Weber; G Lerebours; L Mickalonis; M T Villahermosa
Journal:  Cardiovasc Drugs Ther       Date:  1995-06       Impact factor: 3.727

Review 4.  Perindopril. A review of its pharmacological properties and therapeutic use in cardiovascular disorders.

Authors:  P A Todd; A Fitton
Journal:  Drugs       Date:  1991-07       Impact factor: 9.546

Review 5.  Treatment of hypertension based on both systolic and diastolic pressure could influence the cost of therapy.

Authors:  M Safar
Journal:  Cardiovasc Drugs Ther       Date:  1989-12       Impact factor: 3.727

6.  The response to the first dose of an angiotensin converting enzyme inhibitor in uncomplicated hypertension--a placebo controlled study utilising ambulatory blood pressure recording.

Authors:  R J MacFadyen; A D Bainbridge; K R Lees; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1991-09       Impact factor: 4.335

7.  Antihypertensive Effect and Tolerability of Perindopril in Indian Hypertensive and Type 2 Diabetic Patients: 1-Year Randomised, Double-Blind, Parallel Study vs Atenolol.

Authors:  Y K Seedat; I G Randeree
Journal:  Clin Drug Investig       Date:  1998       Impact factor: 2.859

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.